Clinical efficacy and afety of brinzolamide (Azopt™), a new topical carbonic anhydrae inhibitor for primary open-angle glaucoma and ocular hypertenion Original Reearch Article

PURPOE: To determine the intraocular preure-lowering efficacy and afety of brinzolamide 1.0%, compared with dorzolamide 2.0% and timolol 0.5%. METHOD: A multicenter, double-maked, propective, parallel-group tudy wa conducted to compare brinzolamide 1.0%, adminitered two and three time a day, dorzolamide 2.0% three time a day, and timolol 0.5% twice a day in 572 patient with primary open-angle glaucoma or ocular hypertenion. The primary end point wa diurnally corrected intraocular preure reduction from baeline, evaluated at both peak and trough time during a 3-month period. REULT: Mean intraocular preure change after twice daily (−3.8 to −5.7 mm Hg) and three time daily (−4.2 to −5.6 mm Hg) doing with brinzolamide 1.0% were tatitically equivalent (confidence limit ≤ 1.5 mm Hg) to each other and alo to dorzolamide 2.0% three time a day (−4.3 to −5.9 mm Hg). The range of intraocular preure change with timolol 0.5% twice daily wa −5.2 to −6.3 mm Hg. Clinically relevant intraocular preure change (reduction ≥ 5 mm Hg or intraocular preure ≤ 21 mm Hg) were oberved in up to 75.7% of patient taking brinzolamide twice daily and in up to 80.1% taking brinzolamide three time daily. Treatment with brinzolamide 1.0% wa afe, comfortable, and well tolerated. The incidence of ocular dicomfort (burning and tinging) on intillation of brinzolamide (twice daily, 1.8%; three time daily, 3.0%) wa ignificantly le (P = .000) compared with treatment with dorzolamide (16.4%). CONCLUION: Brinzolamide 1.0% produced clinically relevant intraocular preure reduction in ubtantial number of patient. Brinzolamide’ effectivene equaled that of dorzolamide 2.0% and it produced le ocular dicomfort (burning and tinging) on intillation.